Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
Journal of Translational Medicine
|
April 28, 2016
Changing R&D models in research-based pharmaceutical companies
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder
Drug Discovery Today
|
July 20, 2019
The Art of Virtualizing Pharma R&D
Alexander Schuhmacher, Oliver Gassmann, Michael Kuss, et al.
Drug Discovery Today
|
August 4, 2020
The present and future of project management in pharmaceutical R&D
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, et al.
Journal of Translational Medicine
|
May 10, 2018
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Alexander Schuhmacher, Oliver Gassmann, Nigel McCracken, et al.
Drug Discovery Today
|
August 3, 2024
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023)
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, et al.
Drug Discovery Today
|
July 30, 2013
Models for open innovation in the pharmaceutical industry
Alexander Schuhmacher, Paul-Georg Germann, Henning Trill, et al.
Drug Discovery Today
|
November 15, 2011
Getting the most out of your IP--patent management along its life cycle
Martin A Bader, Oliver Gassmann, Nicole Ziegler, et al.
Drug Discovery Today
|
June 1, 2022
Open innovation: A paradigm shift in pharma R&D?
Alexander Schuhmacher, Oliver Gassmann, Doria Bieniok, et al.
Drug Discovery Today
|
July 6, 2021
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
Alexander Schuhmacher, Clara Brieke, Oliver Gassmann, et al.
Drug Discovery Today
|
April 19, 2026
New perspectives for better R&D performance: lessons learned from leading pharma companies
Alexander Schuhmacher, Oliver Gassmann, Sara Knapp, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
Journal of Translational Medicine
|
April 28, 2016
Changing R&D models in research-based pharmaceutical companies
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder
Drug Discovery Today
|
July 20, 2019
The Art of Virtualizing Pharma R&D
Alexander Schuhmacher, Oliver Gassmann, Michael Kuss, et al.
Drug Discovery Today
|
August 4, 2020
The present and future of project management in pharmaceutical R&D
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, et al.
Journal of Translational Medicine
|
May 10, 2018
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Alexander Schuhmacher, Oliver Gassmann, Nigel McCracken, et al.
Drug Discovery Today
|
August 3, 2024
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023)
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, et al.
Drug Discovery Today
|
July 30, 2013
Models for open innovation in the pharmaceutical industry
Alexander Schuhmacher, Paul-Georg Germann, Henning Trill, et al.
Drug Discovery Today
|
November 15, 2011
Getting the most out of your IP--patent management along its life cycle
Martin A Bader, Oliver Gassmann, Nicole Ziegler, et al.
Drug Discovery Today
|
June 1, 2022
Open innovation: A paradigm shift in pharma R&D?
Alexander Schuhmacher, Oliver Gassmann, Doria Bieniok, et al.
Drug Discovery Today
|
July 6, 2021
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
Alexander Schuhmacher, Clara Brieke, Oliver Gassmann, et al.
Drug Discovery Today
|
April 19, 2026
New perspectives for better R&D performance: lessons learned from leading pharma companies
Alexander Schuhmacher, Oliver Gassmann, Sara Knapp, et al.
Page
of 3